These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8125079

  • 1. The use of chemotherapy in the management of neuroendocrine tumors.
    Oberg K.
    Endocrinol Metab Clin North Am; 1993 Dec; 22(4):941-52. PubMed ID: 8125079
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Chemotherapy of digestive neuroendocrine tumors].
    Rougier P, Toma C, Fabri MC, Ducreux M.
    Ann Gastroenterol Hepatol (Paris); 1995 Dec; 31(2):117-20. PubMed ID: 7618833
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gut neuroendocrine tumors.
    Warner RR.
    Curr Ther Endocrinol Metab; 1997 Dec; 6():606-14. PubMed ID: 9174816
    [No Abstract] [Full Text] [Related]

  • 6. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
    Larsson DE, Hassan S, Larsson R, Oberg K, Granberg D.
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
    Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6111-8. PubMed ID: 15447997
    [Abstract] [Full Text] [Related]

  • 8. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A, Bhatt V.
    Ann Pharmacother; 2012 Jun 15; 46(6):851-62. PubMed ID: 22589450
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME, Wiedenmann B.
    Horm Metab Res; 2011 Nov 15; 43(12):844-53. PubMed ID: 22105475
    [Abstract] [Full Text] [Related]

  • 13. [Treatment strategy of neuroendocrine tumors].
    Ducreux M, Baudin E, Schlumberger M.
    Rev Prat; 2002 Feb 01; 52(3):290-6. PubMed ID: 11925720
    [Abstract] [Full Text] [Related]

  • 14. The role of somatostatin analogs in the management of carcinoid tumors.
    Tomassetti P, Migliori M, Campana D, Brocchi E, Piscitelli L, Tomassetti V, Corinaldesi R.
    J Endocrinol Invest; 2003 Feb 01; 26(8 Suppl):79-81. PubMed ID: 15233219
    [No Abstract] [Full Text] [Related]

  • 15. [Neuroendocrine tumors of the pancreas].
    Gorgone A, Calbo L, Melita G, Riso F, Tigano D, Barbuscia M.
    Chir Ital; 1999 Feb 01; 51(4):309-12. PubMed ID: 10633841
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advances in chemotherapy and biotherapy of endocrine tumors.
    Oberg K.
    Curr Opin Oncol; 1998 Jan 01; 10(1):58-65. PubMed ID: 9466486
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
    Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE.
    Cancer; 1998 Dec 01; 83(11):2293-301. PubMed ID: 9840528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.